The estimated Net Worth of Ronald Silver is at least $1.03 Millón dollars as of 12 August 2024. Mr Silver owns over 3,107 units of Ironwood Pharmaceuticals Inc stock worth over $688,910 and over the last 3 years he sold IRWD stock worth over $341,824.
Mr has made over 11 trades of the Ironwood Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,107 units of IRWD stock worth $13,267 on 12 August 2024.
The largest trade he's ever made was selling 7,908 units of Ironwood Pharmaceuticals Inc stock on 12 February 2024 worth over $120,518. On average, Mr trades about 1,939 units every 73 days since 2021. As of 12 August 2024 he still owns at least 158,370 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Mr Silver stock trades at the bottom of the page.
Ronald Silver is the Corp. Controller & Principal Accounting Officer at Ironwood Pharmaceuticals Inc.
Mr Silver is 39, he's been the Corp. Controller & Principal Accounting Officer of Ironwood Pharmaceuticals Inc since . There are 18 older and 1 younger executives at Ironwood Pharmaceuticals Inc. The oldest executive at Ironwood Pharmaceuticals Inc is Edward Owens, 73, who is the Independent Director.
Ronald's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts y Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: